Glenmark Pharmaceuticals Ltd (GLENMARK) — Announcement | 28 September 2026
Glenmark Pharmaceuticals announced that its trading window for insider transactions will close on October 1, 2026, and remain closed until the unaudited Q2 results for the quarter ending September 30, 2026 are released and for 48 hours thereafter, as required by SEBI regulations.
About Glenmark Pharmaceuticals Ltd (GLENMARK)
Healthcare · Pharmaceuticals · Listed on BSE
📡 Get AI alerts when GLENMARK files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track GLENMARK — Free💡 Ask AI about this filing
📊 More GLENMARK filings
- 🔴 Announcement — 23 September 2026Glenmark Pharmaceuticals announced it received a Voluntary Action Indicated (VAI) classification fro...
- 🔴 Announcement — 21 September 2026Glenmark Pharmaceuticals announced its schedule for upcoming analyst and institutional investor meet...
- 🟡 Voting Results — 11 September 2026Glenmark Pharmaceuticals held its 48th AGM on September 11, 2026 via video conference, approving aud...
- 🔴 Announcement — 11 September 2026Glenmark Pharmaceuticals announced the launch of RYALTRIS Nasal Spray in Brazil for allergic rhiniti...
- 🟡 Board Meeting — 11 September 2026Glenmark Pharmaceuticals held its 48th AGM on September 11, 2026 via video conferencing, where share...
🔥 Also filed on 28 September 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when GLENMARK files new disclosures
Track GLENMARK filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track GLENMARK — FreeFree account · 2 AI queries/day